COVID-19 Patients can induce long-lived bone marrow plasma cell responses
- The new coronavirus may kill cancer cells and achieve a permanent cure!
- Why did the Alzheimer’s drug candidate BACE1 inhibitor fail?
- LRTI Death: Research spanning 80 years confirms for the first time
- The decline of the global antibiotic market is threatening the development of new drugs
- World first: An mRNA vaccine that can 100% protect against deadly bacterial infections is available
- The first successful use of CAR-T cells to treat severe muscle inflammation
University of Washington proved for the first time that patients with mild COVID-19 infection can also induce long-lived bone marrow plasma cell responses
COVID-19 Patients can induce long-lived bone marrow plasma cell responses. On May 24, 2021, Nature published an important article online from WUSTL of Washington University in St. Louis, demonstrating for the first time that SARS-CoV-2 infection can induce the response of long-lived bone marrow plasma cells to produce a durable antibody response.
The commendable part of this study is the acquisition of bone marrow aspiration samples from previously infected persons. I often say that COVID-19 is by far the most thoroughly studied viral infectious disease in humans, because other diseases are not easy to do bone marrow aspiration for patients with acute mild viral infectious diseases with good prognosis.
Long-lived bone marrow plasma cells (BMPC) are a key source of persistent neutralizing antibodies. Although the risk of re-infection of individuals during the recovery period of SARS-CoV-2 is significantly reduced, the SARS-CoV-2 specific antibodies in the peripheral blood of COVID-19 infected persons will rapidly decay within a few months after infection, which has caused academic research. The world speculates whether SARS-CoV-2 infection will induce long-lived BMPC.
This study proved that in patients with mild COVID-19 infection (n = 77), the serum anti-SARS-CoV-2 S protein antibody decreased significantly in the first 4 months after infection, and then in the next 7 The month is gradually decreasing, but it can still be detected 11 months after infection.
The study further found that the anti-S protein neutralizing antibody titers of 18 SARS-CoV-2 recovered patients 7 to 8 months after infection were related to the proportion of S-specific BMPC obtained from their bone marrow aspirate. In contrast, no S-specific BMPC was detected in the bone marrow aspiration of 11 healthy subjects without previous SARS-CoV-2 infection.
This study proves that S-specific BMPCs are stable, indicating that they are part of the immune system’s immune memory in response to SARS-CoV-2 superinfection. This is related to the binding of S protein-specific resting memory B cells in the periphery of recovered patients. .
This study shows that SARS-CoV-2 infection induces a significant antigen-specific persistent immune response in humans.
(source:internet, reference only)
Disclaimer of medicaltrend.org